

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

(37 CFR §1.98(b))

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/P.D./	1	5,077,216	12/31/1991	Morganelli <i>et al.</i>			
	2	5,223,241	06/29/1993	Isobe <i>et al.</i>			
	3	5,747,654	05/05/1998	Pastan <i>et al.</i>			
	4	6,132,992	10/17/2000	Ledbetter <i>et al.</i>			
	5	7,691,588	04/06/2010	Tsuchiya <i>et al.</i>			
	6	2002/0155537	10/24/2002	Carter <i>et al.</i>			
	7	2004/0219643	11/04/2004	Winter <i>et al.</i>			
	8	2005/0214278	09/29/2005	Kakuta <i>et al.</i>			
	9	2005/0267222	12/01/2005	Iwata <i>et al.</i>			
	10	2006/0058511	03/16/2006	Tanikawa <i>et al.</i>			
	11	2006/0159673	07/20/2006	Kojima			
	12	2006/0269989	11/30/2006	Miyazaki <i>et al.</i>			
	13	2007/0087381	04/19/2007	Kojima			
	14	2009/0214535	08/27/2009	Igawa <i>et al.</i>			
	15	2009/0297501	12/03/2009	Igawa <i>et al.</i>			
	16	2010/0015133	01/21/2010	Igawa <i>et al.</i>			
	17	2010/0092457	04/15/2010	Aburatani <i>et al.</i>			
/P.D./	18	2011/0059488	03/10/2011	Tsunoda <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/P.D./	19	AU 2002/210917	05/18/2006	Australia			X	
/P.D./	20	CA 2272245	05/28/1998	Canada				
/P.D./	21	CA 2 331 641	11/11/1999	Canada				
/P.D./	22	EP 437 622	07/24/1991	Europe				
/P.D./	23	EP 0562125	09/29/1993	Europe				
/P.D./	24	EP 0 774 511	05/21/1997	Europe				

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
---------------------------------------	-----------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641
(37 CFR § 1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/P.D./	25	EP 811 691	12/10/1997	Europe				
	26	EP 1 870 458	12/26/2007	Europe				
	27	EP 1 900 814	03/19/2008	Europe				
	28	DE 198 19 846	11/11/1999	Germany			Abstract only	
	29	JP 3-41033	02/21/1991	Japan			Abstract only	
	30	JP 8-500979	02/06/1996	Japan			Abstract only	
	31	JP 2001-523971	11/27/2001	Japan			Abstract only	
	32	JP 2002-543822	12/24/2002	Japan			Abstract only	
	33	JP 2003-515323	05/07/2003	Japan			Abstract only	
	34	JP 2004-292455	10/21/2004	Japan			Abstract only	
	35	WO 91/00739	01/24/1991	WIPO				
	36	WO 93/06862	04/15/1993	WIPO			English abstract	
	37	WO 94/05690	03/17/1994	WIPO				
	38	WO 96/27011	09/06/1996	WIPO				
	39	WO 96/34892	11/07/1996	WIPO				
	40	WO 97/10354	03/20/1997	WIPO			English abstract	
	41	WO 98/22136	05/28/1998	WIPO			English abstract	
	42	WO 98/50431	11/12/1998	WIPO				
	43	WO 00/44788	08/03/2000	WIPO				
	44	WO 00/069462	11/23/2000	WIPO				
	45	WO 01/036486	05/25/2001	WIPO				
	46	WO 01/44282	06/21/2001	WIPO				
	47	WO 01/70775	09/27/2001	WIPO				
	48	WO 02/096457	12/05/2002	WIPO				
	49	WO 03/033538	04/24/2003	WIPO			English abstract	
/P.D./	50	WO 03/086324	10/23/2003	WIPO				

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

(37 CFR §1.98(b))

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/P.D./	51	WO 03/087163	10/23/2003	WIPO			English abstract	
/P.D./	52	WO 2004/019966	03/11/2004	WIPO			English abstract	
/P.D./	53	WO 2004/037293	05/06/2004	WIPO			English abstract	
/P.D./	54	WO 2004/111233	12/23/2004	WIPO			English abstract	
/P.D./	55	WO 2005/107784	11/17/2005	WIPO			English abstract	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/P.D./	56	ANDRIS-WIDHOPF <i>et al.</i> , "Methods for the generation of chicken monoclonal antibody fragments by phage display," <i>Journal of Immunological Methods</i> , 242:159-181 (2000)
/P.D./	57	ARNDT <i>et al.</i> , "Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment," <i>Biochemistry</i> , 37(37):12918-26 (1998)
/P.D./	58	ARNDT <i>et al.</i> , "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107(5):822-829 (2003)
/P.D./	59	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: some practical advice," <i>Pharmaceutical Research</i> , 14(8):969-975 (1997)
/P.D./	60	CARPENTER <i>et al.</i> , "Rational design of stable lyophilized protein formulations: theory and practice," <i>Pharma Biotechnol.</i> , 13:109-133 (2001)
/P.D./	61	CARTER, "Bispecific human IgG by design," <i>J. Immunol. Methods</i> , 248:7-15 (2001)
/P.D./	62	CEKAITE <i>et al.</i> , "Protein Arrays: A versatile toolbox for target identification and monitoring of patient immune responses," <i>Methods Mol. Biol.</i> , 360:335-348 (2007)
/P.D./	63	CHATELLIER <i>et al.</i> , "Functional mapping of conserved residues located at the VL and VH domain interface of a Fab," <i>J. Mol. Biol.</i> , 264(1):1-6 (1996)
/P.D./	64	CHOWDHURY <i>et al.</i> , "Engineering scFvs for improved stability," <i>Methods Mol. Biol.</i> , 207:237-54 (2003)
/P.D./	65	CLACKSON <i>et al.</i> , "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)
/P.D./	66	CLELAND <i>et al.</i> , "A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody," <i>Journal of Pharmaceutical Sciences</i> , 90(3):310-321 (2001)
/P.D./	67	COCHLOVIUS <i>et al.</i> , "Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells," <i>The Journal of Immunology</i> , 165:888-895 (2000)
/P.D./	68	CREIGHTON, T., "Protein folding," <i>Biochem. J.</i> , 270(1):1-16 (1990)
/P.D./	69	DAVIES <i>et al.</i> , "Antibody VH domains as small recognition units," <i>Biotechnology (N.Y.)</i> , 13(5):475-9 (1995)
/P.D./	70	DE JONGE <i>et al.</i> , "Production and Characterization of Bispecific Single-Chain Antibody Fragments," <i>Mol. Immunol.</i> , 32:1405-1412 (1995)

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
-----------------------------------	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

Information Disclosure Statement
by Applicant
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/P.D./	71	ELJISINK <i>et al.</i> , "Rational engineering of enzyme stability," <i>Journal of Biotechnology</i> , 113:105-120 (2004)
	72	EWERT <i>et al.</i> , "Biophysical properties of human antibody variable domains," <i>J. Mol. Biol.</i> , 325:531-553 (2003)
	73	EWERT <i>et al.</i> , "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering," <i>Methods</i> , 34:184-199 (2004)
	74	EWERT <i>et al.</i> , "Structure-based improvement of the biophysical properties of immunoglobulin V _H domains with a generalizable approach," <i>Biochemistry</i> , 42:1517-1528 (2003)
	75	FROKJAER <i>et al.</i> , "Protein drug stability: a formulation challenge," <i>Nature Rev Drug Discov.</i> , 4:298-306 (2005)
	76	GARCIA-GONZALEZ <i>et al.</i> , "Purification of murine IgG3 and IgM monoclonal antibodies by euglobulin precipitation," <i>Journal of Immunological Methods</i> , 111:17-23 (1988)
	77	GenBank: U27005.1, Mus musculus, isolate 7183Liv, Vh7183 Ig heavy chain variable region gene, Vh region, partial cds, 1 page (April 1996)
	78	GenBank: AY081858.1, Mus musculus, isolate H3-9 anti-GBM immunoglobulin kappa chain variable region mRNA, partial cds, 1 page (March 2004)
	79	GOLDSTEIN <i>et al.</i> , "Cytolytic and Cytostatic Properties of an Anti-Human FcγR1 (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," <i>J. Immunol.</i> , 158:872-879 (1997)
	80	GOMBOTZ <i>et al.</i> , "The stabilization of a human IgM monoclonal antibody with poly(vinylpyrrolidone)," <i>Pharmaceutical Research</i> , 11(5):624-632 (1994)
	81	GRUBER <i>et al.</i> , "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>Escherichia coli</i> ," <i>Journal of Immunology</i> , 152:5368-5374 (1994)
	82	HOOGENDOORN <i>et al.</i> , "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," <i>Nucleic Acids Res.</i> , 19:4133-4137 (1991)
	83	HOZUMI and TONEGAWA, "Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions," <i>Proc. Natl. Acad. Sci. USA</i> , 73(10):3628-3632 (1976)
	84	JÄGER <i>et al.</i> , "Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen," <i>Journal of Molecular Biology</i> , 285:2005-2019 (1999)
	85	JUNG <i>et al.</i> , "The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains," <i>J. Mol. Biol.</i> , 309(3):701-16 (2001)
	86	KHALIFA <i>et al.</i> , "Effects on interaction kinetics of mutations at the VH-VL interface of Fabs depend on the structural context," <i>J. Mol. Recognit.</i> , 13(3):127-39 (2000)
	87	KIPRIYANOV and LITTLE, "Generation of Recombinant Antibodies," <i>Molecular Biotechnology</i> , 12:173-201 (1999)
	88	KIPRIYANOV <i>et al.</i> , "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics," <i>Journal of Molecular Biology</i> , 293:41-56 (1999)
/P.D./	89	KONTERMANN, R., "Recombinant bispecific antibodies for cancer therapy," <i>Acta Pharmacol. Sin.</i> , 26(1):1-9 (2005)

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
-----------------------------------	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/P.D./	90	KORN <i>et al.</i> , "Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv," <i>The Journal of Gene Medicine</i> , 6:642-651 (2004)
	91	KREBBER <i>et al.</i> , "Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system," <i>J. Immunol. Methods</i> , 201:35-55 (1997)
	92	KURUCZ <i>et al.</i> , "Retargeting of CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria," <i>The Journal of Immunology</i> , 154:4576-4582 (1995)
	93	LE GALL <i>et al.</i> , "Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody," <i>Protein Engineering Design & Selection</i> , 17(4):357-366 (2004)
	94	LEE <i>et al.</i> , "Reversible dimer formation and stability of the anti-tumour single chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IR spectroscopy," <i>J. Mol. Biol.</i> , 320:107-127 (2002)
	95	LITTLE <i>et al.</i> , "Of mice and men: hybridoma and recombinant antibodies," <i>Immunol. Today</i> , 21:364-370 (2000)
	96	LIU <i>et al.</i> , "Functional interactions between arginine-133 and aspartate-88 in the human reduced folate carrier: evidence for a charge-pair association," <i>Biochem. J.</i> , 358:511-516 (2001)
	97	MAITY <i>et al.</i> , "Equilibrium unfolding of dimeric and engineered monomeric forms of Cro (F58W) repressor and the effect of added salts: evidence for the formation of folded monomer induced by sodium perchlorate," <i>Archives of Biochemistry and Biophysics</i> , 434:93-107 (2005)
	98	MARTSEV <i>et al.</i> , "Antiferritin single-chain antibody: a functional protein with incomplete folding?" <i>FEBS Letters</i> , 441:458-462 (1998)
	99	MCGUINNESS <i>et al.</i> , "Phage diabody repertoires for selection of large number of bispecific antibody fragments," <i>Nature Biotechnology</i> , 14(9):1149-1154 (1996)
	100	MENG <i>et al.</i> , "The evaluation of recombinant, chimeric, tetravalent antihuman CD22 antibodies," <i>Clinical Cancer Research</i> , 10:1274-1281 (2004)
	101	MERCHANT <i>et al.</i> , "An efficient route to human bispecific IgG," <i>Nature Biotechnology</i> , 16:677-681 (1996)
	102	NIEBA <i>et al.</i> , "Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved <i>in vivo</i> folding and physical characterization of an engineered scFv fragment," <i>Protein Engineering</i> , 10(4):435-444 (1997)
	103	NOHAILE <i>et al.</i> , "Altering dimerization specificity by changes in surface electrostatics," <i>PNAS</i> 98(6):3109-3114 (2001)
	104	PEIPP <i>et al.</i> , "Bispecific antibodies targeting cancer cells," <i>Biochem. Soc. Trans.</i> , 30:507-511 (2002)
	105	RAJAGOPAL <i>et al.</i> , "A form of anti-Tac (Fv) which is both single-chain and disulfide stabilized: comparison with its single-chain and disulfide-stabilized homologs," <i>Protein Engineering</i> , 10(12):1453-1459 (1997)
	106	RIDGWAY <i>et al.</i> , "'Knobs-into-holes' engineering of antibody C _H 3 domains for heavy chain heterodimerization," <i>Protein Eng.</i> , 9:617-621 (1996)
/P.D./	107	ROUSCH <i>et al.</i> , "Somatostatin displayed on filamentous phage as a receptor-specific agonist," <i>Br. J. Pharmacol.</i> , 125:5-16 (1998)

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
-----------------------------------	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

Information Disclosure Statement
(Use several sheets if necessary)

(37 CFR §1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/P.D./	108	SEGAL <i>et al.</i> , "Bispecific antibodies in cancer therapy," <i>Current Opinion in Immunology</i> , 11:558-582 (1999)
	109	SHALABY <i>et al.</i> , "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," <i>J. Exp. Med.</i> , 175:217-225 (1992)
	110	SHARMA <i>et al.</i> , "Study of IgM aggregation in serum of patients with macroglobulinemia," <i>Clin Chem Lab Med</i> , 38(8):759-764 (2000)
	111	SHIMBA <i>et al.</i> , "Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody," <i>FEBS Letters</i> , 360:247-250 (1995)
	112	SHIRE <i>et al.</i> , "Challenges in the development of high protein concentration formulations," <i>Journal of Pharmaceutical Sciences</i> , 93(6):1390-1402 (2004)
	113	SKERRA, "Use of the tetracycline promoter for the tightly regulated production of a murine antibody fragment in <i>Escherichia coli</i> ," <i>Gene</i> , 151:131-135 (1994)
	114	TAN <i>et al.</i> , "Contributions of a highly conserved V _H /V _L hydrogen bonding interaction to scFv folding stability and refolding efficiency," <i>Biophysical Journal</i> , 75:1473-1482 (1998)
	115	TANG <i>et al.</i> , "Selection of linkers for a catalytic single-chain antibody using phage display technology," <i>The Journal of Biological Chemistry</i> , 271(26):15682-15686 (1996)
	116	TURNER <i>et al.</i> , "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using phage display technology," <i>Journal of Immunological Methods</i> , 205:43-54 (1997)
	117	VAN DEN BURG <i>et al.</i> , "Selection of mutations for increased protein stability," <i>Curr. Opin. Biotechnol.</i> , 13(4):333-337 (2002)
	118	VARGAS-MADRAZO <i>et al.</i> , "An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues," <i>J. Mol. Recognit.</i> , 16(3):113-20 (2003)
	119	VIEILLE <i>et al.</i> , "Hyperthermophilic enzymes: sources, uses, and molecular mechanisms for thermostability," <i>Microbiology and Molecular Biology Reviews</i> , 65(1):1-43 (2001)
	120	VOLKEL <i>et al.</i> , "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," <i>Protein Engineering</i> , 14(10):815-823 (2001)
	121	WANG <i>et al.</i> , "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 185:129-188 (1999)
	122	WANG <i>et al.</i> , "Lyophilization and development of solid protein pharmaceuticals," <i>International Journal of Pharmaceutics</i> , 203:1-60 (2000)
	123	WANG <i>et al.</i> , "Protein aggregation and its inhibition in biopharmaceutics," <i>International Journal of Pharmaceutics</i> , 289:1-30 (2005)
	124	WHITLOW <i>et al.</i> , "An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability," <i>Protein Engineering</i> , 6(8):989-995 (1993)
	125	WORN <i>et al.</i> , "Stability engineering of antibody single-chain Fv fragments," <i>J. Mol. Biol.</i> , 305:989-1010 (2001)
	126	WU <i>et al.</i> , "Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange," <i>Protein Eng.</i> , 14(12):1025-33 (2001)
/P.D./	127	ZHU <i>et al.</i> , "Remodeling domain interfaces to enhance heterodimer formation," <i>Protein Science</i> , 6:781-788 (1997)

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
---------------------------------------	-----------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

**Information Disclosure Statement
by Applicant**

(Use several sheets if necessary)

(37 CFR § 1.98(b))

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
/P.D./	128	ZHU <i>et al.</i> , "An efficient route to the production of an IgG-like bispecific antibody", <i>Protein Eng.</i> , 13:361-367 (2000)
	129	FISH & RICHARDSON, Amendment in Reply to Action dated April 23, 2010 in U.S. App. Ser. No. 10/530,696, filed October 22, 2010, 8 pages
	130	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/530,696, mailed January 7, 2011, 10 pages
	131	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed December 16, 2010, 5 pages
	132	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Notice of Allowance in U.S. App. Ser. No. 10/551,504, mailed March 21, 2011, 7 pages
	133	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 16, 2010 in U.S. App. Ser. No. 10/582,413, filed October 15, 2010, 11 pages
	134	U.S. EXAMINER BRADLEY DUFFY, USPTO Final Office Action in U.S. App. Ser. No. 10/582,413, mailed December 23, 2010, 12 pages
	135	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed December 9, 2010, 12 pages
	136	U.S. EXAMINER SHULAMITH H. SHAFER, USPTO Restriction Requirement in U.S. App. Ser. No. 12/874,872, mailed December 15, 2010, 6 pages
	137	FISH & RICHARDSON P.C., Reply to Restriction Requirement dated December 15, 2010 in U.S. App. Ser. No. 12/874,872, filed January 18, 2011, 8 pages
	138	U.S. EXAMINER ANNE GUSSOW, USPTO Restriction Requirement in U.S. App. Ser. No. 11/910,117, mailed May 3, 2010, 9 pages
	139	FISH & RICHARDSON P.C., Amendment and Response to Restriction Requirement mailed May 3, 2010 in U.S. App. Ser. No. 11/910,117, filed November 2, 2010, 11 pages
	140	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/910,117, mailed January 24, 2011, 10 pages
	141	International Search Report for App. Ser. No. PCT/JP2006/306800, mailed May 16, 2006, 4 pages
	142	International Preliminary Report on Patentability for App. Ser. No. PCT/JP2006/306800, dated October 3, 2007, 6 pages
	143	European Search Report for App. Ser. No. EP 06 73 0748, dated April 22, 2009, 7 pages
	144	KLARQUIST SPARKMAN, LLP, Amendment in Reply to Action dated September 1, 2009 in U.S. App. Ser. No. 10/582,654, filed February 26, 2010, 11 pages
✓	145	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Final Office Action in U.S. App. Ser. No. 10/582,654, mailed April 6, 2010, 15 pages
/P.D./	146	KLARQUIST SPARKMAN, LLP, Amendment in Reply to Action dated April 6, 2010 in U.S. App. Ser. No. 10/582,654, filed September 21, 2010, 7 pages

Examiner Signature /Pensee Do/	Date Considered 10/02/2011
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	